The FDA amended the emergency use authorizations for COVID-19 vaccines today as follows:
- A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
- A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine may be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.
- A second booster dose of the Moderna COVID-19 Vaccine may be administered at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with the same certain kinds of immunocompromise.
This action is eight days earlier than anticipated, with the FDA having scheduled a meeting of its advisory body VRBPAC several weeks ago for next Wednesday, April 6.
Press Release: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals
Share
Thank you to the many physicians and practice staff who have used this link Revise Requirement to Obtain Patient Consent to Bill After Services Delivered (p2a.co) to send communications to DOH […]
Updated Mandated Reporter Training Requirements. Chapter 56 of the Laws of 2021 amended Social Services Law § 413 to require additional training to include protocols to reduce implicit bias in decision […]
-
On behalf of the entire MSSNY leadership, please accept our sincere gratitude for the successful advocacy campaign that YOU carried out, leading to the outcome of the veto of the Grieving Families Act […]
